Abstract:Although pharmacokinetic and pharmacodynamic differences between the enantiomers of a chiral drug have been known or suspected for many years, racemate drugs have frequently been developed and approved without clinical pharmacologic consideration of their chiral components. In the late 1970s, the technology to isolate, manufacture, and detect pure enantiomers of racemate drugs became generally available. This availability has created new demands on both pharmaceutical firms and regulatory agencies. To prepare for this new technology, the Center for Drug Evaluation and Research at the Food and Drug Administration is formulating a policy statement to guide evaluation of new chiral drugs. At this time, it appears that whatever new policies are developed will not necessarily be applied retroactively to previously approved racemate drugs. Additional policies to guide the development and approval of generic and OTC chiral drugs may be required. In the Office of Generic Drugs in the Center, abbreviated new drug or antibiotic applications are approved on the basis of adequate chemistry, manufacturing, and control procedures and comparative pharmacokinetics (bioequivalence). The generic drug must be a racemate or single enantiomer if the corresponding innovator drug is a racemate or single enantiomer respectively. Whether a generic firm will be required to provide bioequivalence information on enantiomers of a racemate is determined on a case-by-case basis. Although it might be claimed that a generic drug product should be required only to undergo the same general kind of pharmaceutical evaluation as did the innovator, there may be instances when the approval of a generic drug or antibiotic will require measurement of specific enantiomers of a chiral drug.

Chirality of New Drug Approvals (2013-2022): Trends and Perspectives

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes

The significance of chirality in contemporary drug discovery-a mini review

Chirality in New Drug Development

Chiral Switch: Between Therapeutical Benefit and Marketing Strategy

Recent Research Progress of Chiral Small Molecular Antitumor-Targeted Drugs Approved by the FDA From 2011 to 2019

Bioequivalence of racemic drugs

Advancement in chiral heterocycles for the antidiabetic activity

Synthesis of chiral building blocks for use in drug discovery

Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025)

Enantiomeric Analysis of Chiral Drugs Using Mass Spectrometric Methods: A Comprehensive Review

Stereoselective Pharmacokinetics and Chiral Inversions of Some Chiral Hydroxy Group Drugs

Analogues of Anticancer Natural Products: Chiral Aspects

Analyzing the Chiral Purity of Pharmaceuticals: The Application of Cyclodextrin-Based Chiral Selectors in Capillary Electrophoresis

Advances in Enantiomer-Dependent Nanotherapeutics

Enantioselective Transformations in the Synthesis of Therapeutic Agents

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions

Circular Dichroism Sensing: Strategies and Applications

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

Unconventional approaches for chiral resolution

Update on chiral recognition mechanisms in separation science